{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:07:19Z","timestamp":1779268039829,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031893","name":"The Est\u00e9e Lauder Companies","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031893","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Lactation could offer benefit to the mother and child. Information on the safety of lactation during anti-cancer treatment, however, is scarce. Therefore, clinical data about drug exposure through breast milk is needed. To contribute to this, we present a case of a 34-year old woman who was treated with intravenous trastuzumab 600\u00a0mg and pertuzumab 1200\u00a0mg in the first cycle. Over the first 17 days of treatment, she collected breast milk samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Trastuzumab and pertuzumab concentrations in breast milk were determined by validated ELISAs. Subsequently, infant exposure parameters such as infant daily dose (IDD), relative infant dose (RID), and cumulative RID were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cumulative RID was 16.8% for trastuzumab and 24.3% for pertuzumab. Based on our results, we can conclude that intravenously administered trastuzumab and pertuzumab transfer into breast milk exceeding the safety threshold of an RID of 10%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although the extent of systemic exposure in infants after ingestion of breast milk containing these monoclonal antibodies is unknown, systemic exposure cannot be excluded. Therefore, breastfeeding during treatment with trastuzumab and pertuzumab should be discouraged.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00280-026-04901-0","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:20:34Z","timestamp":1779265234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transfer of trastuzumab and pertuzumab into human breast milk: a case report"],"prefix":"10.1007","volume":"96","author":[{"given":"Pauline L. M.","family":"Buitelaar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick","family":"Pluim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Hanssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohan","family":"Kerbage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric C.","family":"Amant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"4901_CR1","unstructured":"NIH National Cancer Institute Breast Cancer - Breast Cancer During Pregnancy. [Internet]. Available from: https:\/\/www.cancer.gov\/types\/breast\/breast-cancer-during-pregnancy. [Accessed December 3 2025]"},{"issue":"1","key":"4901_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ijgo.70258","volume":"171","author":"S Nanda","year":"2025","unstructured":"Nanda S, Nana M, Nguyen-Hoang L, Adam S, McAuliffe F, Bergman L et al (2025) Cancer in pregnancy: FIGO Best practice advice and narrative review. Int J Gynaecol Obstet 171(1):131\u2013151. https:\/\/doi.org\/10.1002\/ijgo.70258","journal-title":"Int J Gynaecol Obstet"},{"key":"4901_CR3","unstructured":"Drugs and Lactation Database (LactMed\u00ae) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development;2006-. Trastuzumab. [Updated 2023 Mar 18]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500579\/. [Accessed December 3 2025]"},{"key":"4901_CR4","unstructured":"Drugs and Lactation Database (LactMed\u00ae) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development;2006-. Pertuzumab. [Updated 2023 Nov 15]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500590\/. [Accessed December 3 2025]"},{"key":"4901_CR5","doi-asserted-by":"publisher","first-page":"115354","DOI":"10.1016\/j.biopha.2023.115354","volume":"166","author":"K de Jong","year":"2023","unstructured":"de Jong K, Damoiseaux D, Pluim D, Rosing H, Beijnen JH, van Thienen H et al (2023) High accumulation of nivolumab in human breast milk: A case report. Biomed Pharmacother 166:115354. https:\/\/doi.org\/10.1016\/j.biopha.2023.115354","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"4901_CR6","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/MCG.0b013e31825f2807","volume":"46","author":"J Fritzsche","year":"2012","unstructured":"Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C (2012) Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol 46(8):718\u2013719. https:\/\/doi.org\/10.1097\/MCG.0b013e31825f2807","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"4901_CR7","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.cell.2021.02.031","volume":"184","author":"C Atyeo","year":"2021","unstructured":"Atyeo C, Alter G (2021) The multifaceted roles of breast milk antibodies. Cell 184(6):1486\u20131499. https:\/\/doi.org\/10.1016\/j.cell.2021.02.031","journal-title":"Cell"},{"key":"4901_CR8","unstructured":"World Health Organization e-Library of Evidence for Nutrition Actions (eLENA). Early initiation of breastfeeding to promote exclusive breastfeeding. [Internet]. Available from: https:\/\/www.who.int\/tools\/elena\/interventions\/early-breastfeeding#:~:text=Breast%20milk%20contains%20all%20the,obesity%20in%20childhood%20and%20adolescence. [Accessed December 3 2025]"},{"issue":"3","key":"4901_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11095-017-2287-z","volume":"35","author":"PO Anderson","year":"2018","unstructured":"Anderson PO (2018) Drugs in Lactation. Pharm Res 35(3):45. https:\/\/doi.org\/10.1007\/s11095-017-2287-z","journal-title":"Pharm Res"},{"key":"4901_CR10","first-page":"70","volume-title":"Drugs and human lactation","year":"1988","unstructured":"Bennett PN (ed) (1988) Drugs and human lactation. Elsevier, Amsterdam, p 70"},{"key":"4901_CR11","doi-asserted-by":"publisher","unstructured":"LaHue SC, Anderson A, Krysko KM, Rutatangwa A, Dorsey MJ, Hale T et al (2020) Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases. Neurol Neuroimmunol Neuroinflamm 7(4). https:\/\/doi.org\/10.1212\/nxi.0000000000000769","DOI":"10.1212\/nxi.0000000000000769"},{"issue":"4","key":"4901_CR12","doi-asserted-by":"publisher","first-page":"e70112","DOI":"10.1111\/bcpt.70112","volume":"137","author":"P Flis","year":"2025","unstructured":"Flis P, Havnen GC, Nordmo E, Asplund A, Wikstr\u00f6m E (2025) Monoclonal Antibodies During Breastfeeding-Challenges With Relative Infant Dose. Basic Clin Pharmacol Toxicol 137(4):e70112. https:\/\/doi.org\/10.1111\/bcpt.70112","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"4901_CR13","doi-asserted-by":"publisher","first-page":"e70116","DOI":"10.1111\/bcpt.70116","volume":"137","author":"O Spigset","year":"2025","unstructured":"Spigset O (2025) Using Relative Infant Dose to Assess Drug Exposure in Breastfed Infants. Basic Clin Pharmacol Toxicol 137(4):e70116. https:\/\/doi.org\/10.1111\/bcpt.70116","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"4901_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s40262-023-01251-5","volume":"62","author":"D Damoiseaux","year":"2023","unstructured":"Damoiseaux D, Centanni D, Beijnen JH, Amant F, Huitema ADR, Dorlo TPC (2023) Predicting Chemotherapy Distribution into Breast Milk for Breastfeeding Women Using a Population Pharmacokinetic Approach. Clin Pharmacokinet 62(7):969\u2013980. https:\/\/doi.org\/10.1007\/s40262-023-01251-5","journal-title":"Clin Pharmacokinet"},{"key":"4901_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3389\/fnut.2020.00130","volume":"7","author":"BNP Sah","year":"2020","unstructured":"Sah BNP, Lueangsakulthai J, Kim BJ, Hauser BR, Woo Y, Olyaei A et al (2020) Partial Degradation of Recombinant Antibody Functional Activity During Infant Gastrointestinal Digestion: Implications for Oral Antibody Supplementation. Front Nutr 7:130. https:\/\/doi.org\/10.3389\/fnut.2020.00130","journal-title":"Front Nutr"},{"issue":"2","key":"4901_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1203\/01.Pdr.0000047663.81816.E3","volume":"53","author":"U Shah","year":"2003","unstructured":"Shah U, Dickinson BL, Blumberg RS, Simister NE, Lencer WI, Walker WA (2003) Distribution of the IgG Fc receptor, FcRn, in the human fetal intestine. Pediatr Res 53(2):295\u2013301. https:\/\/doi.org\/10.1203\/01.Pdr.0000047663.81816.E3","journal-title":"Pediatr Res"},{"issue":"1","key":"4901_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1365-2567.1997.00326.x","volume":"92","author":"EJ Israel","year":"1997","unstructured":"Israel EJ, Taylor S, Wu Z, Mizoguchi E, Blumberg RS, Bhan A et al (1997) Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 92(1):69\u201374. https:\/\/doi.org\/10.1046\/j.1365-2567.1997.00326.x","journal-title":"Immunology"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04901-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04901-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04901-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:20:36Z","timestamp":1779265236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04901-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4901"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04901-0","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"11 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fr\u00e9d\u00e9ric C. Amant: MiMARK Diagnostics (Advisory Board, Institutional, financial interest), Est\u00e9e Lauder (Funding, Institutional, financial interest), ESGO (council member, non-financial interest). The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Informed consent of the involved patient was obtained before starting breast milk sampling and treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent"}},{"value":"The patient gave permission to publish the research results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"53"}}